This page is updated frequently with new Colorectal-related patent applications.
|Method for colorectal cancer detection|
The present invention provides an oligopeptide specific to colorectal cancer cells, which are selected from a group of peptide sequences consisting of seq id: no. 1 to seq id: no.
National Tsing Hua University
|Detecting colorectal neoplasm|
Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as colorectal cancer.. .
Exact Sciences Corporation
|Method for supporting diagnosis of risk of colorectal cancer recurrence, treatment of colorectal cancer, and administration of anticancer drug|
Disclosed is a method for supporting a diagnosis of a risk of colorectal cancer recurrence, including the steps of: performing a first measurement to measure the levels of expression of a plurality of genes selected from a first gene group present in a region from 18q21 to 18q23 on the long arm of chromosome 18 in a biological sample collected from a patient with colorectal cancer, a second measurement to measure the levels of expression of a plurality of genes selected from a second gene group present in a region from 20q11 to 20q13 on the long arm of chromosome 20, and a third measurement to measure the levels of expression of a plurality of genes selected from a third gene group including angptl2, axl, c1r, c1s, calhm2, ctsk, dcn, emp3, grem1, itgav, klhl5, mmp2, rab34, selm, srgap2p1, and vim; and determining the risk of colorectal cancer recurrence of the patient based on the levels of expression measured in the measurement step.. .
|Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer|
Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from table 2 or table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided.
Almac Diagnostics Limited
|Colorectal cancer drug, and predicting prognosis of colorectal cancer patient|
The purpose of the present invention is to provide a colorectal cancer drug that uses microrna exhibiting outstanding effectiveness in colorectal cancer patients, particularly colorectal cancer patients having a mutated kras gene. Mir4689 and/or mir4685-3p can suppress the growth of colorectal cancer cells, particularly colorectal cancer cells having a mutated kras gene, and thus exhibit an effective antitumor effect..
|Mir-320e and colorectal cancer|
Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of mirna such as mir-320e in the patients. Embodiments provide predictive, prognostic and/or diagnostics methods by identifying mirnas that are useful for clinical management of cancer patients, particularly colorectal cancer patients or patients at risk or determined to have colorectal cancer.
Baylor Research Institute
|Treatment of cancer|
In one aspect, the disclosure features, a method of treating a cancer, e.g. colorectal cancer, e.g., rectal cancer, in a subject with a cyclodextrin containing polymer (“cdp”)-camptothecin conjugate, particle or composition or camptothecin derivative conjugate, particle or composition described herein, e.g., crlx101.
Cerulean Pharma Inc.
|Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer|
Methods and kits for identifying a subject having pre-cancerous advanced polyps or colorectal cancer based on the expression profile(s) of specific mrna biomarkers. Methods and kits for diagnosing, preventing, managing therapy, monitoring and identifying predisposition to colorectal cancer..
Bio-marcare Technologies Ltd.
|Histone deacetylase inhibitors|
Fused bicycle indol, indoline, azoindole, or azoindoline compounds of formula (i) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same.
National Health Research Institutes
|Methods for preventing or reducing colon carcinogenesis|
The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient in need thereof an antioxidant effective amount of a compound represented by formula i, iia or iib as disclosed herein..
Nogra Pharma Limited
Treatment planning and evaluation for rectal cancer via image analytics
Methods and apparatus associated with predicting colorectal cancer tumor invasiveness are described. One example apparatus includes a set of circuits, and a data store that stores radiological images of tissue demonstrating colorectal cancer.
Case Western Reserve University
Therapeutic molecules & deviates for crc
The chemically synthesized compound tricin 7-o-beta-d-glucopyranoside, native to the plant deschampsia antarctica and present in aqueous extracts of the plant deschampsia antarctica said compound having the ability to inhibit tumor growth in mammals with colorectal carcinoma.. .
Methods and biomarkers for analysis of colorectal cancer
The present invention relates to methods and biomarkers (e.g., protein biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer, providing a prognosis to colorectal cancer patients, and in companion diagnostics..
Oslo Universitetssykehus Hf
G-alpha interacting vesicle associated protein (giv) as a predictive marker in stage ii colorectal cancer
Provided herein are methods of analyzing stage ii colorectal cancer (crc) samples (such as those that are mis-match repair proficient, pmmr), by scoring g-alpha interacting vesicle associated protein (giv, also known as girdin) full-length (giv-fl) expression in combination with lymphovascular invasion (lvi) status or clinical variables. The disclosed methods can be used to identify giv-fl expressing tumors that are likely to recur (high risk) and those that are not likely to recur (high risk).
Hoffmann-la Roche, Inc.
Detection of elevated levels of phosphorylated mcm and increasing mcm phosphorylation capacity
Identified herein is a novel post-translational modification of mcm2, wherein the residue of serines 53 and 108 are phosphorylated. Ddk phosphorylates mcm2 at serines 53 and 108 when stimulated by treslin.
The Florida State University Research Foundation, Inc.
Composition or kit for diagnosing colorectal cancer incluidng cxcl7-measuring agent and diagnosing colorectal cancer using the same
Provided are a composition or a kit for diagnosing colorectal cancer including a cxcl7-measuring agent, and a method of diagnosing colorectal cancer using the same. According to the composition or the kit, and the method, colorectal cancer may be simply diagnosed with high diagnostic accuracy and specificity for colorectal cancer..
Samsung Life Public Welfare Foundation
Method and apparatus to diagnose the metastatic or progressive potential of cancer, fibrosis and other diseases
A method and apparatus for determining the progressive potential of a disease is disclosed. The forward to backward propagating second harmonic generation signal derived from a second harmonic generation instrument is used to assess the collagen microstructure of imaged body tissue by way of numerical values that are in turn used to determine the progressive or metastatic potential of the disease.
University Of Rochester
Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
Provided herein are compositions, method and uses for modulating iap activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (daso) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of birc6, ciap1 or survivin.
Duocarmycin adcs showing improved in vivo antitumor activity
The present invention relates to duocarmycin-containing antibody-drug conjugates (adcs) for use in the treatment of human solid tumours and haematological malignancies expressing her2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing adcs for use in the treatment of human solid tumours with her2 ihc 2+ or 1+ and her2 fish negative tissue status.
Synthon Biopharmaceuticals B.v.
Method for detecting an increased risk or incidence of colorectal cancer
The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis.
Siemens Healthcare Diagnostics Inc.
Armet as a marker for cancer
Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=armet) as a universal marker of different cancer types.
Roche Diagnostics Operations, Inc.
Methods for diagnosing a colorectal cancer (crc) health state or change in crc health state, or for diagnosing risk of developing crc or the presence of crc in a subject
The present invention relates to the diagnosis of colorectal and ovarian cancers (crc and oc, respectively). The present invention describes the relationship between endogenous small molecules and crc or oc.
Phenomenome Discoveries Inc.
Hjurp peptides and vaccines including the same
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic t cell inducibility of the original sequence.
Oncotherapy Science, Inc.
Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.. .
Mayo Foundation For Medical Education And Research
Gene methylation based colorectal cancer diagnosis
The invention provides method of identifying a colorectal cancer in a sample comprising dna from a subject, determining the methylation status of one or more of the genes selected from boll, cdx1, clic4, dcc, esr1, gata4, gdnf, hla-g, jub, myod1, nkx2-1, penk, pitx2, ptgs2, rarb, s100a2, sall3, sez6l, sfrp2, sparc, tceb2, tfpi2, thbd, tjp2, tmeff2, tp53, twist1, wt1 or combinations thereof and comparing the methylation status with a control, thereby identifying colorectal cancer dna in the sample and means for performing the inventive method.. .
Tecnet Equity NÖ Technologiebeteiligungs-invest Gmbh
1 -(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as raf inhibitors for the treatment of cancer
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea compounds (referred herein as “tbap compounds”) that, inter alia, inhibit raf (e.g., braf, craf, etc.).
Institute Of Cancer Research: Royal Cancer Hospital (the)
Transforming Growth Factor
Follow us on Twitter
This listing is a sample listing of patent applications related to Colorectal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Colorectal with additional patents listed. Browse our RSS directory or Search for other possible listings.